Record Q3 and year-to-date results with strong revenue and profit growth, led by Americas and Asia-Pacific. Imaging and cardiac products showed robust performance, while EMEA lagged due to high market penetration. Outlook remains positive, with focus on U.S., China, and vascular segment expansion.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.